Pleven

• A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU … Recruiting
  2023-507372-42-00 4 2021-09-20 Schizophrenia
• A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting
  2023-507202-14-00 7 2021-04-29 Upper limb spasticity after stroke or traumatic brain injury
• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i … Recruiting
  2023-504417-67-00 6 2020-12-22 Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Sp
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with chronic inflammatory demyel … Recruiting
  2023-507885-21-00 4 2020-08-18 Chronic Inflammatory Demyelinating Polyneuropathy
• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Recruiting
  2023-508956-20-00 5 2020-03-12 Hidradenitis suppurativa
• A Study Evaluating BFB759 in Atopic Dermatitis Ended recruitment
  2025-521624-30-00 4 2026-01-08 Atopic dermatitis
• A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis Ended recruitment
  2025-522113-35-00 4 2026-01-07 Atopic dermatitis
• SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended recruitment
  2025-521791-63-00 4 2025-12-18 Moderately to Severely Active Rheumatologic Disease
• Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended recruitment
  2024-516295-14-00 4 2025-09-17 Treatment of Sjögren’s disease
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici … Ended recruitment
  2025-521127-73-00 5 2025-09-12 Relapsing forms of Multiple Sclerosis
• A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended recruitment
  2024-514680-26-00 4 2025-07-17 Agitation Associated with Alzheimer’s Dementia
• Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants … Ended recruitment
  2024-512319-40-00 5 2025-07-01 Subjects with relapsing multiple sclerosis (relapsing remitting MS or
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT … Ended recruitment
  2024-515523-11-00 5 2025-06-09 Chronic Weight Management
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended recruitment
  2024-515672-12-00 5 2025-05-27 Moderate to Severe Genital Psoriasis
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended recruitment
  2023-509239-19-00 5 2025-04-03 Active Psoriatic Arthritis
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• A 24-Week Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF) ( … Ended recruitment
  2024-514283-40-00 4 2024-12-19 Pulmonary Hypertension
• A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended recruitment
  2024-511738-11-00 5 2024-12-18 Psoriatic arthritis
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis

Showing 121–144 of 284 trials